GVHD the first step, page-94

First 94 Last

Share
Profile

Follow
ddwn

12,556 Posts.

3394

20/12/22

20:12

Post #: 65389690
Share

Originally posted by whytee: ↑

Well at least he attempts an in depth analysis based around the facts that have been disclosed.

Its way better than the personal attacks and sniping from people who have blind faith and make no effort to discern what's going in anything approaching a realistic appraisal of facts.

But the facts are these:

1. The company received a CRL on their first submission of the BLA
2. The company's description of the control group in the aGVHD wasn't accurate and as the result, the FDA didn't accept the single arm trial result as valid.
3. The company said it would resubmit the BLA addressing all the problems raised by the FDA 2 years ago. It hasn't done so yet.
4. The company is accused of misleading investors about the quality of the trial results and prospects for approval in multiple class action law suits in the USA and Australia. Most are still in progress and one was settled out of court for $2m.
5. It was leaked by one of the company's officers that they had problems with the new potency assay they were going to submit to the FDA, and they have had to revert to the original one.
6. The company has further said it has to rely on the "totality of the evidence" in the hope of persuading the FDA to give limited approval.
7. $30m of the funds the company says are available credit will cease to exist in a week or so as the funding agreement expires on Dec 31.
8. The company loses around $80-$100m every year and needs to keep around $60m in available cash to meet loan covenants and operating expenses. By early next year they will probably need to address funding.
9. Major partners/investors such as TEVA and Novartis have walked away
10. Every major trial the company has been involved with has failed to achieve the primary end points.

It's just hard to find anything that would give investors a real chance to get their money back. The only thing in its favour is the loyalty of a small hard core of faithful investors hoping to redeem their losses. The company's track record of actual achievement doesn't give any real cause for comfort.

Expand

On MSB, we have to agree to disagree as I'm a glass half full whilst you don't even hold a glass

I can counter every point that you've listed, but I won't as I prefer to enjoy taking my dog for a walk.
I leave you with one thought, the market has pretty much priced in most of the items that you've listed - but, what about the upside?

We'll find out soon enough - which one of us is right on MSB
I don't like where the SP is at, but I'm actually not stressed

MSB Price at posting: 92.5¢ Sentiment: Buy Disclosure: Held
15 Upvote

2 Great analysis

Reply

Top Stories

Failure to report prompts ASX to impose multiple company suspensions

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

LU7

Strong PFS numbers solidify Lithium Universe's big plans for Québec

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

IRE

Iress runs 'hot' for Wealth Within's stock tips

There are more pages in this discussion • 146 more messages in this thread...

First 94 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.21		Change 0.040(3.42%)		Mkt cap ! $1.381B

Open	High	Low	Value	Volume
$1.17	$1.22	$1.17	$5.683M	4.776M

Buyers (Bids)

No.	Vol.	Price($)
1	20000	$1.21

Sellers (Offers)

Price($)	Vol.	No.
$1.21	19746	3

View Market Depth

No.	Vol.	Price($)
1	20000	1.205
2	55500	1.200
3	60292	1.195
1	33180	1.190
3	67965	1.185

Price($)	Vol.	No.
1.210	19746	3
1.215	45236	7
1.220	190559	15
1.225	70181	4
1.230	169274	5

Last trade - 16.10pm 01/10/2024 (20 minute delay)

MSB (ASX) Chart

GVHD the first step, page-94

Failure to report prompts ASX to impose multiple company suspensions

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Iress runs 'hot' for Wealth Within's stock tips

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

GVHD the first step, page-94

Top Stories

Failure to report prompts ASX to impose multiple company suspensions

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Strong PFS numbers solidify Lithium Universe's big plans for Québec

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Iress runs 'hot' for Wealth Within's stock tips

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News